FDA Releases Interim Response to AbbVie’s Citizen Petition

Article

FDA released an interim response to AbbVie’s citizen petition on the labeling of biosimilars.

FDA released an interim response to AbbVie’s June 2015 citizen petition on the labeling of biosimilars, in a Dec. 1, 2015 letter to the company.

According to the letter, FDA has not yet reached a decision on the petition, which requests FDA to clearly label biosimilars under 351 (k) Public Health Services Act. The agency said they were unable to reach a decision on the petition because it rose, “complex issues requiring extensive review and analysis by Agency officials.”

In the petition, AbbVie argued labels should reference whether or not a biosimilar is licensed for fewer uses than its reference biologic. The petition also brought up issues of interchangeability, stating labels should contain information on whether or not the biosimilar is interchangeable with the reference.

In an August 2015 amendment to the petition, AbbVie said it is also misleading to include information from a study not performed on the biosimilar itself on the label. The company asserts there should be a clear distinction between data derived from studies done on the reference biologic and on the biosimilar.

The petition launched after discrepancies arose with the labeling of Sandoz’s Zarxio, a biosimilar of Amgen’s neutropenia medication Neupogen (filgrastim). Zarxio’s label includes information from studies done on filgrastim, rather than on Zarxio. AbbVie called Zarxio’s label a “shortcoming to FDA’s current approach to biosimilar labeling.”

FDA says they will respond to AbbVie’s petition when they have reached a final decision-they did not provide information about when a decision would be released. 

Source: FDA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
© 2025 MJH Life Sciences

All rights reserved.